Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
Part of paid clinical trials in Cincinnati, Ohio.
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Study ID
- NCT07477197
- Status
- Recruiting
Conditions
- Adult Congenital Heart Disease
- Connective Tissue Disease
- Other Cardiovascular Conditions
- Pulmonary Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.
Key Dates
- Start date
- Jul 1, 2021
- Status verified
- Mar 2026
- Primary completion
- Jan 1, 2050
- Completion
- Jan 1, 2050
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: No treatment
Primary Outcome Measure
Successful establishment of biospecimen repository [ Time Frame: Day 1 ]
Central Contacts
- Sasha Opotowsky, MD513-803-2243
- Lindsay Fist
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital Medical Center, Cincinnati | Cincinnati | Ohio | 45229 | - |
Find similar trials in Cincinnati, OH
By research site
Related Studies
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Pulmonary Hypertension Association RegistryRecruiting · Pulmonary Hypertension Association, Inc. · Phoenix, Arizona
- Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension SystemRecruiting · Aria CV, Inc · La Jolla, California
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFPHASE3 · Recruiting · Tenax Therapeutics, Inc. · Tucson, Arizona